Drug intelligence / Profile preview

lactobacillus plantarum + lactobacillus salivarius

Development stage: Unknown
Lead developer: Wuxi Children's Hospital
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral, Vaginal, Topical

Overview

Lactobacillus plantarum + lactobacillus salivarius is a probiotic combination of two live bacterial strains. This specific combination is being investigated in clinical trials for its potential to treat halitosis (bad breath). The proposed mechanism involves modulating the oral microbiome by increasing the abundance of beneficial bacteria while reducing odor-producing pathogenic bacteria, such as *Fusobacterium nucleatum*, and consequently lowering the levels of volatile sulfur compounds (VSCs) which are the primary cause of bad breath. [15, 17, 19] A clinical trial for this indication is sponsored by Wuxi Children's Hospital and Jiangnan University. [23] While this specific two-strain combination has not been identified with a commercial brand name, other probiotic products containing these strains, often in combination with others like *Lactobacillus brevis*, are available for different indications such as bacterial vaginosis. [18]

Other names: Lactobacillus plantarum CCFM1214 + Lactobacillus salivarius CCFM1215

Beyond the preview

Go deeper on lactobacillus plantarum + lactobacillus salivarius.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on lactobacillus plantarum + lactobacillus salivarius.

Explore the full profile